Asceneuron will attend the upcoming BIO International Convention next week, June 5-8 in Boston, MA! Our team is excited to connect with pharmaceutical executives to explore partnering and strategic opportunities in Alzheimer’s disease.
Our flagship clinical program, the OGA enzyme inhibitor ASN51, is a small molecule with confirmed long-lasting CNS target engagement in the human brain. The program is approaching Phase 2 at an accelerated pace. By targeting the toxic misfolding of proteins in the brain, ASN51 aims to effectively block tau pathology, thereby halting the progression of Alzheimer's disease.
We are looking forward to meeting with you at BIO!